4.6 Article

Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment

Journal

ALZHEIMERS RESEARCH & THERAPY
Volume 8, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s13195-016-0172-3

Keywords

-

Funding

  1. National Institutes of Health [NIH] [U01 AG024904]
  2. U.S. Department of Defense [W81XWH-12-2-0012]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. AbbVie
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Araclon Biotech
  9. BioClinica, Inc.
  10. Biogen
  11. Bristol-Myers Squibb
  12. CereSpir, Inc.
  13. Eisai Inc.
  14. Elan Pharmaceuticals, Inc.
  15. Eli Lilly and Company
  16. EuroImmun
  17. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  18. Fujirebio
  19. GE Healthcare
  20. IXICO Ltd.
  21. Janssen Alzheimer Immunotherapy Research & Development, LLC
  22. Johnson & Johnson Pharmaceutical Research & Development LLC
  23. Lumosity
  24. Lundbeck
  25. Merck Co., Inc.
  26. Meso Scale Diagnostics, LLC
  27. NeuroRx Research
  28. Neurotrack Technologies
  29. Novartis Pharmaceuticals Corporation
  30. Pfizer Inc.
  31. Piramal Imaging
  32. Servier
  33. Takeda Pharmaceutical Company
  34. Transition Therapeutics
  35. Canadian Institutes of Health Research
  36. NIH [R00 EB009106, K23 NS080988]

Ask authors/readers for more resources

Background: Semiquantitative methods such as the standardized uptake value ratio (SUVR) require normalization of the radiotracer activity to a reference tissue to monitor changes in the accumulation of amyloid-beta (A beta) plaques measured with positron emission tomography (PET). The objective of this study was to evaluate the effect of reference tissue normalization in a test-retest F-18-florbetapir SUVR study using cerebellar gray matter, white matter (two different segmentation masks), brainstem, and corpus callosum as reference regions. Methods: We calculated the correlation between F-18-florbetapir PET and concurrent cerebrospinal fluid (CSF) A beta(1-42) levels in a late mild cognitive impairment cohort with longitudinal PET and CSF data over the course of 2 years. In addition to conventional SUVR analysis using mean and median values of normalized brain radiotracer activity, we investigated a new image analysis technique-the weighted two-point correlation function (wS(2))-to capture potentially more subtle changes in A beta-PET data. Results: Compared with the SUVRs normalized to cerebellar gray matter, all cerebral-to-white matter normalization schemes resulted in a higher inverse correlation between PET and CSF A beta(1-42), while the brainstem normalization gave the best results (high and most stable correlation). Compared with the SUVR mean and median values, the wS(2) values were associated with the lowest coefficient of variation and highest inverse correlation to CSF A beta(1-42) levels across all time points and reference regions, including the cerebellar gray matter. Conclusions: The selection of reference tissue for normalization and the choice of image analysis method can affect changes in cortical F-18-florbetapir uptake in longitudinal studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available